Myasthenie.com

Clin Chim Acta. 2025 Apr 24:120330. doi: 10.1016/j.cca.2025.120330. Online ahead of print.

ABSTRACT

BACKGROUNDS: Myasthenia gravis (MG) is an autoimmune disease predominantly caused by anti-acetylcholine receptor antibodies (AChR-Abs). In this study, the relationship between MG relapse and AChR-Abs concentration were investigated.

METHODS: We retrospectively reviewed the clinical records of 41 patients with AChR-Abs-positive MG. Data collected included age, sex, MG status within 12 months (untreated status, UTMG; recurrence status, RCMG), MG subgroups, QMGs, AChR-Abs concentration and treatments. The relative change rate (RCR) of AChR-Abs concentration was calculated as: RCR(%)=(AChR-Abs-AChR-AbsUTMG)/AChR-AbsUTMG/month*100. ROC curve analysis and binary logistic regression analyses were used to evaluate the association between these factors and MG recurrence.

RESULTS: Within 12 months, 12 patients experienced a recurrence (RCMG). A weak correlation was observed between AChR-Abs level in UTMG and QMGs (r = 0.336, p = 0.032). MG subgroups, QMGs, AChR-Ab levels and RCR differed significantly between RCMG and non-RCMG group. Single factor ROC curves indicated that AChR-Abs concentration, RCR and MG subgroups were related to MG recurrence (AUC = 0.724, 0.736, 0.736). Combining with RCR and MG subgroups, the ROC yielded an AUC of 0.899, demonstrating high sensitivity and specificity.

CONCLUSION: RCR of AChR-Abs was correlated with MG progression, and repeated AChR-Abs measurements can assist in monitoring disease status and guiding therapeutic decision-making.

PMID:40286896 | DOI:10.1016/j.cca.2025.120330


Source: https://pubmed.ncbi.nlm.nih.gov/4028689 ... t9+e462414